Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vitamin K dose-finding for warfarin reversal
ACTRN12612000665831Phase 2Recruiting
- Sponsor
- Dr. Noel Chan
- Start
- Jul 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of phytomenadione and warfarin in venous thromboembolism (VTE) (5 arms), sponsored by Dr. Noel Chan. Primary endpoint: Lowest effective dose of oral vitamin K1 for INR reversal. Started Jul 2012; status: recruiting.
02
Drugs
phytomenadionewarfarin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ACTRN12612000665831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000665831.